Takeda Pharmaceutical Company Limited and ASKA Pharmaceutical Co., Ltd. announced that they entered inter a licensing agreement to grant ASKA exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of Takeda-owned relugolix. Relugolix is being developed as a gonadotropin-releasing receptor antagonist to be taken orally once daily against uterine fibroids, endometriosis and prostate cancer. Under this agreement, no right of relugolix for prostate cancer treatment in Japan has been granted to ASKA.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,378 JPY | +0.76% | +5.22% | +33.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.30% | 43Cr | |
+38.59% | 73TCr | |
-7.89% | 35TCr | |
+15.66% | 33TCr | |
+0.24% | 28TCr | |
+13.47% | 24TCr | |
+7.35% | 21TCr | |
-6.42% | 20TCr | |
+4.23% | 16TCr | |
-1.70% | 16TCr |
- Stock Market
- Equities
- 4886 Stock
- News ASKA Pharmaceutical Holdings Co.,Ltd.
- ASKA Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited Enter into Licensing Agreement for Relugolix in Women's Health Indications